Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

ClearPoint Neuro, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SOLANA BEACH, CALIFORNIA / ACCESS NEWSWIRE / SEPTEMBER 25, 2025 / CLEARPOINT NEURO, INC. (NASDAQ:CLPT) (THE "COMPANY"), A GLOBAL DEVICE, CELL, AND GENE THERAPY-ENABLING COMPANY OFFERING PRECISE NAVIGATION TO THE BRAIN AND SPINE, TODAY ANNOUNCED THAT DR. PAUL LARSON WILL BE JOINING THE COMPANY AS CHIEF MEDICAL OFFICER STARTING IN JANUARY 2026. DR. LARSON HAS A LONG HISTORY OF WORKING WITH CLEARPOINT NEURO AS AN ADVISOR, ESPECIALLY SUPPORTING EDUCATION AND PRODUCT DEVELOPMENT EFFORTS RELATED TO CELL AND GENE THERAPY DELIVERY.

CLEARPOINT NEURO ANNOUNCES THE APPOINTMENT OF DR. PAUL LARSON AS CHIEF MEDICAL OFFICER

SOLANA BEACH, CALIFORNIA / ACCESS NEWSWIRE / SEPTEMBER 4, 2025 / CLEARPOINT NEURO, INC. (NASDAQ:CLPT) (THE "COMPANY"), A GLOBAL DEVICE, CELL, AND GENE THERAPY-ENABLING COMPANY OFFERING PRECISE NAVIGATION TO THE BRAIN AND SPINE, TODAY ANNOUNCED THAT THE CLEARPOINT PRISM NEURO LASER THERAPY SYSTEM ("CLEARPOINT PRISM") RECEIVED 510(K) CLEARANCE FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) TO INCLUDE 1.5T MRI GUIDANCE IN ADDITION TO THE PREVIOUSLY CLEARED 3T MRI GUIDANCE. THIS EXPANDED LABELING COULD SIGNIFICANTLY INCREASE CLEARPOINT PRISM'S MARKET OPPORTUNITY WITHIN THE UNITED STATES, WHERE 1.5T MRI SYSTEMS ACCOUNT FOR APPROXIMATELY 60% OF CLINICAL USE.1 AS THE COMPANY CONSIDERS FUTURE DEVELOPMENT WITHIN KEY MARKETS, 1.5T SYSTEMS REPRESENT OVER 70% OF THE GLOBAL INSTALLED MRI BASE,2 WELL-POSITIONING CLEARPOINT PRISM FOR FUTURE GROWTH AS THE COMPANY CONTINUES TO EXPAND INTERNATIONALLY.

CLEARPOINT NEURO ANNOUNCES FDA CLEARANCE EXPANDING COMPATIBILITY OF THE CLEARPOINT PRISM NEURO LASER THERAPY SYSTEM WITH 1.5T MRI SCANNERS

RECORD REVENUE AND SUBSTANTIAL CASH INFUSION HIGHLIGHT THE COMPANY'S FAST. FORWARD.' STRATEGY SOLANA BEACH, CA / ACCESS NEWSWIRE / AUGUST 12, 2025 / CLEARPOINT NEURO, INC. (NASDAQ:CLPT) (THE "COMPANY"), A GLOBAL DEVICE, CELL, AND GENE THERAPY-ENABLING COMPANY OFFERING PRECISE NAVIGATION TO THE BRAIN AND SPINE, TODAY ANNOUNCED FINANCIAL RESULTS FOR ITS SECOND QUARTER ENDED JUNE 30, 2025.

CLEARPOINT NEURO REPORTS SECOND QUARTER 2025 RESULTS

SOLANA BEACH, CALIFORNIA / ACCESS NEWSWIRE / AUGUST 4, 2025 / CLEARPOINT NEURO, INC. (NASDAQ:CLPT) ("COMPANY"), A GLOBAL DEVICE, CELL, AND GENE THERAPY-ENABLING COMPANY OFFERING PRECISE NAVIGATION TO THE BRAIN AND SPINE, TODAY ANNOUNCED MULTIPLE KEY MILESTONES DEMONSTRATING THE PROGRESSION OF THE COMPANY'S BIOLOGICS AND DRUG DELIVERY PORTFOLIO INCLUDING FIRST COMMERCIAL INFUSIONS IN THE UNITED STATES, ADDITIONAL PARTNERS ACCEPTED FOR EXPEDITED REVIEW, CREATION OF CELL AND GENE INFUSION ICD-10 CODES, AND RECORD CLINICAL TRIAL PATIENTS TREATED GLOBALLY IN THE MONTH OF JULY. THE FIRST COMMERCIAL TREATMENTS FOR KEBILIDI (ELADOCAGENE EXUPARVOVEC-TNEQ), A GENE THERAPY APPROVED FOR PEDIATRIC AND ADULT PATIENTS WITH AROMATIC L-AMINO ACID DECARBOXYLASE (AADC) DEFICIENCY-A RARE, LIFE-THREATENING NEUROLOGICAL DISORDER, HAVE BEEN PERFORMED IN THE UNITED STATES USING THE COMPANY'S SMARTFLOW NEURO CANNULA.

CLEARPOINT NEURO ANNOUNCES PROGRESSION OF KEY PARTNER MILESTONES THROUGHOUT THE GLOBAL BIOLOGICS AND DRUG DELIVERY PORTFOLIO

SOLANA BEACH, CALIFORNIA / ACCESS NEWSWIRE / JULY 23, 2025 / CLEARPOINT NEURO, INC. (NASDAQ:CLPT) (THE "COMPANY"), A GLOBAL DEVICE, CELL, AND GENE THERAPY-ENABLING COMPANY OFFERING PRECISE NAVIGATION TO THE BRAIN AND SPINE, TODAY ANNOUNCED THAT IT WILL RELEASE FINANCIAL RESULTS FOR ITS 2025 SECOND QUARTER ON TUESDAY, AUGUST 12TH, AFTER THE MARKET CLOSE. INVESTORS AND ANALYSTS ARE INVITED TO LISTEN TO THE LIVE BROADCAST REVIEW OF THE COMPANY'S 2025 SECOND QUARTER ON TUESDAY, AUGUST 12TH AT 4:30 P.M.

CLEARPOINT NEURO TO ANNOUNCE SECOND QUARTER 2025 RESULTS AUGUST 12, 2025

RECORD REVENUE HIGHLIGHTED BY 70% GROWTH IN SINGLE-USE NAVIGATION AND THERAPY PRODUCTS SOLANA BEACH, CALIFORNIA / ACCESS NEWSWIRE / MAY 13, 2025 / CLEARPOINT NEURO, INC. (NASDAQ:CLPT) (THE "COMPANY"), A GLOBAL DEVICE, CELL, AND GENE THERAPY-ENABLING COMPANY OFFERING PRECISE NAVIGATION TO THE BRAIN AND SPINE, TODAY ANNOUNCED FINANCIAL RESULTS FOR ITS FIRST QUARTER ENDED MARCH 31, 2025. FIRST QUARTER HIGHLIGHTS REPORTED RECORD QUARTERLY REVENUE OF $8.5 MILLION, AN 11% YEAR-OVER-YEAR INCREASE COMPARED WITH THE FIRST QUARTER OF 2024; GREW TOTAL CONSUMABLE PRODUCT REVENUE BY $2.6 MILLION YEAR-OVER-YEAR, OR 104%, INCLUDING BIOLOGICS AND DRUG DELIVERY CANNULAS, SMARTFRAME FAMILY NAVIGATION DEVICES, AND CLEARPOINT PRISM LASER THERAPY APPLICATORS; RECEIVED FDA CLEARANCE FOR THE CLEARPOINT 3.0 SOFTWARE WHICH INCLUDES BOTH OPERATING ROOM NAVIGATION CAPABILITY AND ENHANCED LASER THERAPY FEATURES.

CLEARPOINT NEURO REPORTS FIRST QUARTER 2025 RESULTS

SOLANA BEACH, CALIFORNIA / ACCESS NEWSWIRE / MAY 12, 2025 / CLEARPOINT NEURO, INC. (NASDAQ:CLPT) (THE "COMPANY"), A GLOBAL DEVICE, CELL, AND GENE THERAPY-ENABLING COMPANY OFFERING PRECISE NAVIGATION TO THE BRAIN AND SPINE, TODAY ANNOUNCED THAT IT HAS ENTERED INTO A NOTE FINANCING ARRANGEMENT WITH OBERLAND CAPITAL MANAGEMENT LLC ("OBERLAND CAPITAL") OF UP TO $105 MILLION, WITH $30.0 MILLION OF GROSS PROCEEDS FUNDED AT CLOSING. ADDITIONAL NOTE FINANCING WILL BE PROVIDED TO THE COMPANY BY OBERLAND CAPITAL UNDER THE FOLLOWING TERMS: AN ADDITIONAL $25.0 MILLION AT THE OPTION OF THE COMPANY ANY TIME PRIOR TO DECEMBER 31, 2026; AND AN ADDITIONAL $50.0 MILLION AT THE OPTION OF THE COMPANY AND OBERLAND CAPITAL ANY TIME PRIOR TO DECEMBER 31, 2026.

CLEARPOINT NEURO ANNOUNCES INVESTMENT OF UP TO $110 MILLION BY OBERLAND CAPITAL WITH $33.5 MILLION FUNDED AT CLOSING

SOLANA BEACH, CA / ACCESS NEWSWIRE / APRIL 25, 2025 / CLEARPOINT NEURO, INC. (NASDAQ:CLPT) (THE "COMPANY"), A GLOBAL DEVICE, CELL, AND GENE THERAPY-ENABLING COMPANY OFFERING PRECISE NAVIGATION TO THE BRAIN AND SPINE, TODAY ANNOUNCED THAT IT WILL RELEASE FINANCIAL RESULTS FOR ITS 2025 FIRST QUARTER ON TUESDAY, MAY 13TH, AFTER THE MARKET CLOSE. INVESTORS AND ANALYSTS ARE INVITED TO LISTEN TO THE LIVE BROADCAST REVIEW OF THE COMPANY'S 2025 FIRST QUARTER ON TUESDAY, MAY 13TH, AT 4:30 P.M.

CLEARPOINT NEURO TO ANNOUNCE FIRST QUARTER 2025 RESULTS MAY 13, 2025

ACHIEVED RECORD REVENUE FOR 2024 AND GROWTH OF 31%; REDUCED 2024 OPERATIONAL CASH BURN BY 35% SOLANA BEACH, CALIFORNIA / ACCESS NEWSWIRE / FEBRUARY 26, 2025 / CLEARPOINT NEURO, INC. (NASDAQ:CLPT) (THE "COMPANY"), A GLOBAL DEVICE, CELL, AND GENE THERAPY-ENABLING COMPANY OFFERING PRECISE NAVIGATION TO THE BRAIN AND SPINE, TODAY ANNOUNCED FINANCIAL RESULTS FOR ITS FOURTH QUARTER AND FULL-YEAR ENDED DECEMBER 31, 2024. 2024 FULL YEAR AND FOURTH QUARTER HIGHLIGHTS REPORTED FOURTH QUARTER 2024 REVENUE OF $7.8 MILLION, A 14% YEAR-OVER-YEAR INCREASE COMPARED WITH THE FOURTH QUARTER OF 2023; REPORTED REVENUE OF $31.4 MILLION FOR THE FULL YEAR 2024, AN INCREASE OF 31% OVER 2023 AND REPRESENTING THE TENTH CONSECUTIVE YEAR OF GROWTH; OVERALL PRODUCT REVENUE, INCLUDING BIOLOGICS AND DRUG DELIVERY, GREW 76% TO $18.6 MILLION FOR THE FULL YEAR AS A RESULT OF THE SMARTFRAME OR PLATFORM AND CLEARPOINT PRISM LASER THERAPY SYSTEM AND PARTNER PROGRESSION IN CLINICAL TRIALS; ACTIVATED SIX NEW GLOBAL CENTERS IN THE FOURTH QUARTER FOR A TOTAL OF 25 NEW CENTERS IN 2024, APPROXIMATELY THREE TIMES OUR HISTORIC ACTIVATION RATE; CONTINUED PATIENT ENROLLMENT IN NUMEROUS CELL AND GENE THERAPY TRIALS FOR PARTNERS SELECTED IN FDA EXPEDITED REVIEW PROGRAMS ACROSS MULTIPLE INDICATIONS; FULL EARLY REPAYMENT OF THE PRINCIPAL AMOUNT AND INTEREST ON A $10 MILLION CONVERTIBLE NOTE LEAVING THE COMPANY WITH NO OUTSTANDING DEBT; QUARTERLY OPERATIONAL CASH BURN OF $1.2 MILLION, BRINGING TOTAL 2024 OPERATIONAL CASH BURN OF $9.0 MILLION, A REDUCTION OF 35% VERSUS 2023; AND REPORTED CASH AND CASH EQUIVALENTS TOTALING $20.1 MILLION AS OF DECEMBER 31, 2024.

CLEARPOINT NEURO REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS

SOLANA BEACH, CA / ACCESS NEWSWIRE / FEBRUARY 14, 2025 / CLEARPOINT NEURO, INC. (NASDAQ:CLPT) (THE "COMPANY"), A GLOBAL DEVICE, CELL, AND GENE THERAPY-ENABLING COMPANY OFFERING PRECISE NAVIGATION TO THE BRAIN AND SPINE, TODAY ANNOUNCED THAT IT WILL RELEASE FINANCIAL RESULTS FOR ITS 2024 FOURTH QUARTER AND FULL YEAR ON WEDNESDAY, FEBRUARY 26TH, AFTER THE MARKET CLOSE. INVESTORS AND ANALYSTS ARE INVITED TO LISTEN TO THE LIVE BROADCAST REVIEW OF THE COMPANY'S 2024 FOURTH QUARTER AND FULL YEAR RESULTS ON WEDNESDAY, FEBRUARY 26TH, AT 4:30 P.M.

CLEARPOINT NEURO TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2024 RESULTS FEBRUARY 26, 2025

SOLANA BEACH, CA / ACCESS NEWSWIRE / FEBRUARY 12, 2025 / CLEARPOINT NEURO, INC. (NASDAQ:CLPT) (THE "COMPANY"), A GLOBAL DEVICE, CELL, AND GENE THERAPY-ENABLING COMPANY OFFERING PRECISE NAVIGATION TO THE BRAIN AND SPINE, TODAY ANNOUNCED RECEIPT OF EUROPEAN MEDICAL DEVICE REGULATION (EU MDR) APPROVAL FOR THE SMARTFLOW NEURO CANNULA. THE SMARTFLOW CANNULA WAS PREVIOUSLY CLEARED UNDER THE MEDICAL DEVICE DIRECTIVE 93/42/EEC (MDD) AND HAS NOW SUCCESSFULLY ACHIEVED THE MORE RIGOROUS EU MDR CERTIFICATION WELL AHEAD OF THE 2027 DEADLINE FOR CLASS III DEVICES.

ClearPoint Neuro, Inc.

CLPT

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ClearPoint Neuro, Inc.

CLPT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CLPT